The Supreme Court says the FTC can take action against deals struck between brand-name drug...


The Supreme Court says the FTC can take action against deals struck between brand-name drug makers and manufacturers seeking to market generics. The case stems from FTC v. Actavis and revolves around so-called "reverse-payment agreements," so named because the holder of a patent makes a payment to the generic challenger as opposed to the other way around. Some say the agreements amount to the splitting of monopoly profits at the expense of the public. Shares of Actavis (ACT -1.7%) fall on the news and Abbvie (ABBV +0.1%) trades largely flat after slipping initially.

From other sites
Comments (1)
  • hwyram
    , contributor
    Comments (4) | Send Message
     
    It seems these generic companies are ONLY there to make money at the expense of the consumer and their health. Isn't this like Legal Stealing. More control and close watch needs to be kept on these so called "Legit" transactions. Actavis nee Watson is a major player in this conspiracy.
    12 Jul 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs